Literature DB >> 9333037

Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions.

D L Shinabarger1, K R Marotti, R W Murray, A H Lin, E P Melchior, S M Swaney, D S Dunyak, W F Demyan, J M Buysse.   

Abstract

The oxazolidinones are a new class of synthetic antibiotics with good activity against gram-positive pathogenic bacteria. Experiments with a susceptible Escherichia coli strain, UC6782, demonstrated that in vivo protein synthesis was inhibited by both eperezolid (formerly U-100592) and linezolid (formerly U-100766). Both linezolid and eperezolid were potent inhibitors of cell-free transcription-translation in E. coli, exhibiting 50% inhibitory concentrations (IC50s) of 1.8 and 2.5 microM, respectively. The ability to demonstrate inhibition of in vitro translation directed by phage MS2 RNA was greatly dependent upon the amount of RNA added to the assay. For eperezolid, 128 microg of RNA per ml produced an IC50 of 50 microM whereas a concentration of 32 microg/ml yielded an IC50 of 20 microM. Investigating lower RNA template concentrations in linezolid inhibition experiments revealed that 32 and 8 microg of MS2 phage RNA per ml produced IC50s of 24 and 15 microM, respectively. This phenomenon was shared by the translation initiation inhibitor kasugamycin but not by streptomycin. Neither oxazolidinone inhibited the formation of N-formylmethionyl-tRNA, elongation, or termination reactions of bacterial translation. The oxazolidinones appear to inhibit bacterial translation at the initiation phase of protein synthesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9333037      PMCID: PMC164082     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Preparation and assay of purified Escherichia coli polysomes devoid of free ribosomal subunits and endogenous GTPase activities.

Authors:  T Girbés; B Cabrer; J Modolell
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

2.  An in vitro coupled transcription-translation system from Staphylococcus aureus.

Authors:  R Mahmood; P Compagnone-Post; S A Khan
Journal:  Gene       Date:  1991-09-30       Impact factor: 3.688

3.  Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound.

Authors:  J S Daly; G M Eliopoulos; S Willey; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

4.  Parameters for the preparation of Escherichia coli ribosomes and ribosomal subunits active in tRNA binding.

Authors:  H J Rheinberger; U Geigenmüller; M Wedde; K H Nierhaus
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

5.  The mechanism of action of DuP 721, a new antibacterial agent: effects on macromolecular synthesis.

Authors:  D C Eustice; P A Feldman; A M Slee
Journal:  Biochem Biophys Res Commun       Date:  1988-02-15       Impact factor: 3.575

6.  Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis.

Authors:  D C Eustice; P A Feldman; I Zajac; A M Slee
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

7.  Misreading of RNA codewords induced by aminoglycoside antibiotics.

Authors:  J Davies; L Gorini; B D Davis
Journal:  Mol Pharmacol       Date:  1965-07       Impact factor: 4.436

8.  Comparison of the misreading induced by streptomycin and neomycin.

Authors:  L Grisé-Miron; J Noreau; P Melançon; L Brakier-Gingras
Journal:  Biochim Biophys Acta       Date:  1981-11-27

9.  Effect of base sequence on in vitro protein-chain termination.

Authors:  M C Ganoza; K Buckingham; P Hader; T Neilson
Journal:  J Biol Chem       Date:  1984-11-25       Impact factor: 5.157

10.  Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721.

Authors:  A M Slee; M A Wuonola; R J McRipley; I Zajac; M J Zawada; P T Bartholomew; W A Gregory; M Forbes
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

View more
  71 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis.

Authors:  S H Marshall; C J Donskey; R Hutton-Thomas; R A Salata; L B Rice
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

3.  Linezolid induced toxic optic neuropathy.

Authors:  K Kulkarni; L V Del Priore
Journal:  Br J Ophthalmol       Date:  2005-12       Impact factor: 4.638

4.  In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.

Authors:  Cédric Jacqueline; Dominique Navas; Eric Batard; Anne-Françoise Miegeville; Virginie Le Mabecque; Marie-France Kergueris; Denis Bugnon; Gilles Potel; Jocelyne Caillon
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

5.  In vitro activities of novel 2-fluoro-naphthyridine-containing ketolides.

Authors:  Darren Abbanat; Glenda Webb; Barbara Foleno; Y Li; Mark Macielag; Deborah Montenegro; Ellyn Wira; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 6.  Linezolid: a review of its use in the management of serious gram-positive infections.

Authors:  C M Perry; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection.

Authors:  Daniela Baldoni; Manuel Haschke; Zarko Rajacic; Werner Zimmerli; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

8.  R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance.

Authors:  Eugene Skripkin; Timothy S McConnell; Joseph DeVito; Laura Lawrence; Joseph A Ippolito; Erin M Duffy; Joyce Sutcliffe; François Franceschi
Journal:  Antimicrob Agents Chemother       Date:  2008-07-28       Impact factor: 5.191

Review 9.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Pharmacokinetics of linezolid in subjects with renal dysfunction.

Authors:  Michael E Brier; Dennis J Stalker; George R Aronoff; Donald H Batts; Kristi K Ryan; Margaret O'Grady; Nancy K Hopkins; Gail L Jungbluth
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.